Anti-inflammatory research peptides
The anti-inflammatory peptide class spans small NF-κB-targeting tripeptides (KPV), broader cytokine modulators (BPC-157, GHK-Cu), and direct anti-fibrotic compounds (AC-SDKP, pentosan polysulfate).
Chronic and dysregulated inflammation underlies a broad spectrum of pre-clinical disease models — from bowel disease and skin conditions to cardiac fibrosis and joint degeneration — and the compounds in this category have each been studied for the capacity to interrupt specific nodes in the inflammatory signalling network. Rather than broad immunosuppression, the research interest lies in selective interference with the principal pro-inflammatory transcription factor NF-κB and with downstream catabolic mediators such as TGF-β1, MMP-13, and pro-inflammatory cytokines, while leaving the regenerative dimensions of the immune response intact. This selectivity is both the scientific appeal and an unresolved challenge in the translation of these compounds. NF-κB pathway suppression is the mechanism shared in varying degrees by most compounds in this category. KPV, as the C-terminal tripeptide of α-MSH, enters intestinal epithelial cells and macrophages via the PepT1 transporter and directly reduces nuclear translocation of NF-κB p65 and IκBα phosphorylation (Dalmasso et al., J Proteome Res, 2010), reducing IL-1β and TNF-α transcription without requiring melanocortin receptor engagement. BPC-157 similarly attenuates TNF-α, IL-6, and IL-1β in colitis and muscle-injury models while simultaneously preserving the angiogenic and proliferative healing response through its NO and VEGFR2 systems — a combination that makes it mechanistically unique among anti-inflammatory research peptides. The TB-500 fragment LKKTETQ reduces NF-κB p65 nuclear translocation in LPS-stimulated macrophages with parallel decreases in TNF-α and IL-6 secretion (Huang et al., J Cardiovasc Pharmacol, 2012), consistent with a shared property across thymosin-beta-4 family members. GHK-Cu adds an anti-fibrotic dimension by suppressing TGF-β1-driven Smad-2/3 phosphorylation and myofibroblast differentiation, whilst modulating the MMP/TIMP balance in favour of organised remodelling rather than uncontrolled fibrogenesis (Zhou et al., Int J Mol Med, 2014). Pentosan polysulfate (PPS) approaches the inflammatory cascade from a matrix-degradation angle: it is a potent inhibitor of MMP-3, MMP-13, and ADAMTS-4 in cartilage and synovial tissue, and reduces IL-1β-stimulated IL-6 and PGE2 in synoviocyte cultures, producing an anti-catabolic profile that complements its direct inhibition of matrix-degrading enzymes. Within this category, the compounds differ substantially in molecular scale, target specificity, and tissue focus. KPV (342 Da) is the smallest and most narrowly focused, acting almost exclusively at mucosal and epidermal immune interfaces. BPC-157 (1419 Da) has the broadest multi-system pre-clinical profile — tendon, gut, vascular, neural — but is concentrated in a single research network. AC-SDKP (487 Da) is distinguished by its endogenous status as a thymosin-beta-4-derived tetrapeptide constitutively generated in vivo and rapidly cleared by ACE, making it a link between the renin-angiotensin system and tissue fibrosis that is amplified by ACE-inhibitor therapy. Pentosan polysulfate (4,000–6,000 Da polymer) is the only compound with regulatory approval in some jurisdictions (as Elmiron for interstitial cystitis in the US) and with a well-documented human safety concern — cumulative macular toxicity — that is absent from the other compounds in this group. Common pre-clinical assay systems include LPS-stimulated RAW 264.7 or peritoneal macrophage cultures for NF-κB nuclear translocation (EMSA or immunofluorescence), ELISA quantification of TNF-α, IL-1β, IL-6, and PGE2 in cell-culture supernatants, and DSS or TNBS rodent colitis models with histological scoring. Anti-fibrotic endpoints are assessed by Sirius Red staining for collagen area fraction, alpha-SMA immunostaining for myofibroblast density, and hydroxyproline quantification in tissue digests. In the UK, none of these compounds is MHRA-authorised for human anti-inflammatory use. Pentosan polysulfate holds UK veterinary authorisation for dogs and horses. BPC-157 is WADA-prohibited under S0; AC-SDKP and KPV are likely captured by WADA's S0 category for non-approved substances. Key unresolved questions include whether the anti-inflammatory properties of BPC-157 are separable from its angiogenic activity for targeted research applications, whether AC-SDKP's anti-fibrotic profile is sufficiently durable to constitute a monotherapy in chronic fibrotic disease, and the safety implications of GHK-Cu's broad transcriptional footprint in the context of neoplastic or ageing tissue.
Peptides in this category
BPC-157
Body Protection Compound 157 · PL 14736 · Pentadecapeptide BPC 157
A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.
TB-500
Thymosin Beta-4 fragment · Tβ4 17-23 · TB500
A synthetic peptide commonly described as a fragment of thymosin beta-4 incorporating the actin-binding 'LKKTETQ' motif. Studied for soft-tissue repair, wound healing, and cardiac tissue regeneration in animal models.
GHK-Cu
Copper tripeptide-1 · Glycyl-L-histidyl-L-lysine:copper(II)
A naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with Cu(II). Extensively studied in dermatology for wound healing, collagen synthesis, antioxidant defence, and hair-follicle stimulation.
Thymosin Beta-4
Tβ4 · TMSB4X · Full-length thymosin beta-4 · RGN-352
A 43-amino-acid actin-sequestering peptide expressed in nearly all human cells. Distinct from the shorter TB-500 fragment; investigated in cardiac repair, corneal healing, neural regeneration, and dermal regeneration.
Pentosan Polysulfate
PPS · PPS sodium · Elmiron · Cartrophen · SP54
A semi-synthetic sulfated polysaccharide investigated in osteoarthritis, interstitial cystitis, and connective-tissue research for its chondroprotective, anti-inflammatory, and anticoagulant effects — with a critical long-term safety signal regarding pigmentary maculopathy.
KPV
α-MSH 11-13 · Lysine-Proline-Valine tripeptide · alpha-MSH C-terminal fragment
A three-amino-acid C-terminal fragment of α-MSH studied for its anti-inflammatory effects in colitis, atopic skin conditions, and mucosal healing models — without the pigmentary effects of full-length MSH.
AC-SDKP (TB-500 Fragment)
AcSDKP · N-acetyl-Ser-Asp-Lys-Pro · Goralatide · Acetyl-Ser-Asp-Lys-Pro · N-Acetyl-SDKP
A naturally occurring N-terminal tetrapeptide released from thymosin beta-4 by prolyl oligopeptidase. AC-SDKP circulates endogenously, is rapidly degraded by angiotensin-converting enzyme (ACE), and is studied primarily for anti-fibrotic, pro-angiogenic, and haematopoietic regulatory effects across cardiac, renal, and pulmonary tissue.
Relevant research stacks
Tendon & Ligament Research Stack
Combine peptides studied for soft-tissue, vascular, and cellular-migration effects in tendon and ligament repair research.
Gut Healing Research Stack
Examine complementary effects on mucosal repair, inflammatory cytokine release, and tight-junction integrity in pre-clinical gut models.
Skin & Wound Healing Research Stack
Address dermal collagen synthesis, angiogenesis, and antimicrobial defence in pre-clinical wound-healing models.
Post-Surgical Recovery Research Stack
Combine peptides studied for anastomotic integrity, wound-edge vascularisation, and connective-tissue repair in pre-clinical post-operative models.
Athletic Injury Recovery Research Stack
Cover the heterogeneous tissue injury profile seen in athletic injury models — combining tendon, muscle, dermal, and antimicrobial peptide research candidates in one combined research arm.
Post-Cycle Soft-Tissue Recovery Research Stack
Investigate combined peptide effects on soft-tissue and cartilage repair in post-exercise and post-cycle recovery research models.
Anti-Aging Skin Research Stack
Explore combined effects on dermal collagen and elastin synthesis, cellular ageing markers, and antimicrobial barrier integrity in skin-research models.
Mucosal Immune Defence Research Stack
Address the three mechanistic axes of mucosal defence — anti-inflammatory cytokine suppression, antimicrobial peptide activity, and tight-junction barrier integrity — in pre-clinical gut-immunity models.
Immune Research Stack — Thymic Peptide Framework
Combine mechanistically distinct immune-modulator research peptides — thymic-lineage T-cell maturation (thymosin alpha-1), zinc-dependent thymic immune modulation (thymulin), antimicrobial host-defence (LL-37), and NF-κB-suppression anti-inflammatory (KPV) — to explore multi-mechanism immune pharmacology in pre-clinical research models.
Relevant comparisons
BPC-157 vs TB-500
BPC-157 and TB-500 are the two most-discussed research peptides in soft-tissue repair. They have overlapping interest areas — tendon, ligament, and vascular healing — but operate by different mechanisms and rest on quite different bodies of evidence.
GHK-Cu vs TB-500
GHK-Cu and TB-500 are sometimes grouped together as 'tissue-repair peptides', but the two operate at very different scales — GHK-Cu primarily as a transcriptional modulator of dermal fibroblasts, TB-500 primarily as a cell-migration peptide.
KPV vs LL-37
KPV and LL-37 occupy overlapping but distinct niches in the inflammation–antimicrobial peptide space. KPV is small, charge-neutral, and primarily anti-inflammatory; LL-37 is larger, cationic, and combines direct antimicrobial activity with broad immunomodulation.
BPC-157 vs AOD-9604
Both BPC-157 and AOD-9604 are discussed in the context of post-injury recovery, but they originate from very different research programmes and target different tissues.
TB-500 vs Thymosin Beta-4
TB-500 is widely described as a fragment of thymosin beta-4, but in the research-chemical market the molecular identity supplied under the TB-500 label is not always defined. This comparison clarifies the relationship between the synthetic research peptide and the endogenous parent molecule, and discusses which to choose for a given research question.
KPV vs Larazotide
KPV and larazotide are both studied for gut-barrier indications but operate at completely different points in the mucosal pathology cascade. KPV suppresses NF-κB-driven inflammatory cytokine release inside mucosal cells; larazotide blocks zonulin-receptor signalling at the apical tight junction. The two are mechanistically complementary rather than substitutes — and one has progressed to Phase IIb clinical trials while the other has not.
Epitalon vs GHK-Cu
Epitalon and GHK-Cu are both grouped under 'anti-aging' peptide research but address different biological axes. Epitalon is a synthetic tetrapeptide studied for telomerase upregulation and pineal-related effects; GHK-Cu is a naturally occurring copper-binding tripeptide with the deepest dermal regenerative evidence base of any non-prescription peptide ingredient.
BPC-157 vs Larazotide
BPC-157 and larazotide both have gut-healing applications but operate at completely different points in mucosal biology. BPC-157 supports mucosal angiogenesis and ulcer healing through a broad pro-regenerative profile; larazotide blocks zonulin-driven tight-junction disassembly to prevent paracellular antigen leak. The two can be studied independently or in combination for layered gut-barrier research.
Thymosin Alpha-1 vs Thymosin Beta-4
Thymosin Alpha-1 and Thymosin Beta-4 share the historical 'thymosin' name because both were originally isolated from the same bovine thymic Fraction 5 preparation by Allan Goldstein's laboratory in the 1970s. Despite the naming, they are structurally, mechanistically, and pharmacologically distinct compounds addressing entirely different biological processes. Thymosin Alpha-1 is an immune-modulator; Thymosin Beta-4 is an actin-binding tissue-repair peptide. This comparison clarifies the differentiation that the confusing shared naming can obscure.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.